Astrazeneca's (AZN) Imfinzi in combination with chemotherapy has been approved in the European Union for the treatment of adults with operable non-small cell lung cancer.
The specific indication for the treatment of patients at high risk of recurrence and no epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements, the company said Friday.
Under the treatment plan, patients are treated with the drug, also known as durvalumab, in combination with neoadjuvant chemotherapy before surgery and as an adjuvant monotherapy after surgery, the company said.
The European Commission approval follows a positive opinion issued by the Committee for Medicinal Products for Human Use as well as results from a clinical trial in which the drug resulted in a 32% reduction in recurrence, progression, or death vs patients treated with chemotherapy alone, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.